

Instance: composition-en-4c889264e6df1e0383b0ef68358c4009
InstanceOf: CompositionUvEpi
Title: "Composition for sivextro Package Leaflet"
Description:  "Composition for sivextro Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp46f820f4ed55a5408360fa9c2e65bd6e)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - sivextro"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Sivextro is and what it is used for</li>
<li>What you need to know before you take Sivextro</li>
<li>How to take Sivextro</li>
<li>Possible side effects</li>
<li>How to store Sivextro</li>
<li>Contents of the pack and other information</li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What sivextro is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What sivextro is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Sivextro is an antibiotic that contains the active substance tedizolid phosphate. It belongs to a group of
medicines called  oxazolidinones .
It is used to treat adults and adolescents 12 years of age and older with infections of the skin and
tissues below the skin.
It works by stopping the growth of certain bacteria which can cause serious infections.</p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take sivextro"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take sivextro"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Sivextro 
* if you are allergic to tedizolid phosphate or any of the other ingredients of this medicine (listed
in section 6). 
Warnings and precautions
Your doctor will have decided if Sivextro is suitable to treat your infection.
Talk to your doctor or nurse before taking Sivextro if any of the following apply to you:</p>
<ul>
<li>are suffering from diarrhoea, or have suffered from diarrhoea whilst (or up to 2 months after)
taking antibiotics in the past.</li>
<li>are allergic to other medicines belonging to the group  oxazolidinones  (e.g., linezolid,
cycloserine).</li>
<li>have a history of bleeding or easy bruising (which may be a sign of low numbers of platelets,
the small cells involved in clotting in your blood).</li>
<li>have kidney problems.</li>
<li>are taking certain medicines to treat depression, known as tricyclics, SSRIs (selective serotonin
reuptake inhibitors) or MAOIs (monoamine oxidase inhibitors). See Other medicines and
Sivextro for examples.</li>
<li>are taking certain medicines to treat migraine known as  triptans . See Other medicines and
Sivextro for examples.
Ask your doctor or pharmacist if you are not sure whether you are taking any of these medicines.
Diarrhoea
Contact your doctor straight away if you suffer from diarrhoea during or after your treatment. Do not
take any medicine to treat your diarrhoea without first checking with your doctor.
Resistance to antibiotics
Bacteria can become resistant to treatment with antibiotics over time. This is when antibiotics cannot
stop the growth of bacteria and treat your infection. Your doctor will decide if you should be given
Sivextro to treat your infection. 
Possible side effects
Certain side effects have been observed with Sivextro or another member of the oxazolidinone class
when administered over a duration exceeding that recommended for Sivextro. Tell your doctor straight
away if you suffer from any of the following while taking Sivextro:</li>
<li>a low white blood cell count </li>
<li>anaemia (low red blood cells) </li>
<li>bleeding or bruising easily</li>
<li>loss of sensitivity in your hands or feet (such as numbness, prickling/tingling, or sharp pains)</li>
<li>any problems with your eyesight such as blurred vision, changes in colour vision, difficulty in
seeing detail or if your field of vision becomes restricted.
Children
This medicine should not be used in children under 12 years of age as it has not been studied enough
in this population.
Other medicines and Sivextro
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other
medicines. It is especially important that you tell your doctor if you are also taking:</li>
<li>amitriptyline, citalopram, clomipramine, dosulepin, doxepin, fluoxetine, fluvoxamine,
imipramine, isocarboxazid, lofepramine, moclobemide, paroxetine, phenelzine, selegiline and
sertraline (used to treat depression)</li>
<li>sumatriptan, zolmitriptan (used to treat migraine)</li>
<li>imatinib, lapatinib (used to treat cancer)</li>
<li>methotrexate (used to treat cancer, rheumatoid arthritis or psoriasis)</li>
<li>sulfasalazine (used to treat inflammatory bowel diseases)</li>
<li>topotecan (used to treat cancer)</li>
<li>statins such as pitavastatin, rosuvastatin (used to lower blood cholesterol)
Sivextro can interfere with the effects of these medicines. Your doctor will explain more.
Pregnancy and breast-feeding 
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask
your doctor or pharmacist for advice before taking this medicine.
It is not known if Sivextro passes into breast milk in humans. Ask your doctor for advice before
breast-feeding your baby.
Driving and using machines
Do not drive or use machines if you feel dizzy or tired after taking this medicine. </li>
</ul>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take sivextro"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take sivextro"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor
or pharmacist if you are not sure.
The recommended dose is one 200 mg tablet once a day for 6 days. The tablets are swallowed whole
and can be taken with or without food or drink.<br />
Talk to a doctor if you do not feel better, or if you feel worse after 6 days.
If you take more Sivextro than you should
Contact your doctor, pharmacist or nearest hospital casualty department as soon as possible if you
have taken more tablets than you should, and take your medicine with you.
If you forget to take Sivextro
If you forget to take your medicine, take the dose as soon as possible anytime up to 8 hours prior to the
next scheduled dose. If less than 8 hours remains before the next dose, then wait until the next
scheduled dose. Do not take a double dose to make up for a forgotten dose. If in any doubt, contact
your pharmacist for advice.
You should take all 6 tablets to complete your course of treatment, even if you have missed a dose.
If you stop taking Sivextro
If you stop taking Sivextro without the advice of your doctor, your symptoms may get worse. Talk to
your doctor or pharmacist before you stop taking your medicine.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.
Contact your doctor straight away if you suffer from diarrhoea during or after your treatment.
Other side effects may include:
Common side effects (may affect up to 1 in 10 people)
* Nausea
* Vomiting
* Headache
* Itching all over the body
* Tiredness
* Dizziness
Uncommon side effects (may affect up to 1 in 100 people)
* Fungal infections of skin, mouth and vagina (oral / vaginal thrush)
* Itching (including itching due to allergic reaction), hair loss, acne, red and/or itchy rash or hives,
excessive sweating 
* Decrease or loss of skin sensitivity, tingling/prickling skin sensation 
* Hot flush or blushing/redness in the face, neck or upper chest 
* Abscess (swollen, pus-filled lump) 
* Vaginal infection, inflammation or itching 
* Anxiety, irritability, shaking or trembling 
* Respiratory tract (sinuses, throat and chest) infection
* Dryness in the nose, congestion in the chest, cough 
* Sleepiness, abnormal sleep pattern, difficulty sleeping, nightmares (unpleasant/disturbing
dreams)
* Dry mouth, constipation, indigestion, pain/discomfort in the belly (abdomen), retching, dry
heaving, bright red blood in the stool
* Acid reflux disease (heartburn, pain or difficulty swallowing), flatulence/passing wind 
* Joint pain, muscle spasms, back pain, neck pain, pain/discomfort in limbs, decrease of grip
strength
* Blurred vision,  floaters  (small shapes seen floating in the field of vision)
* Swollen or enlarged lymph nodes 
* Allergic reaction 
* Dehydration 
* Poor control of diabetes 
* Abnormal sense of taste 
* Slow heartbeat
* Fever 
* Swelling in ankles and/or feet 
* Abnormal smelling urine, abnormal blood tests 
Frequency not known (frequency cannot be estimated from the available data)
* Bleeding or bruising easily (due to low numbers of platelets, the small cells involved in clotting
in your blood)
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects
not listed in this leaflet. You can also report side effects directly via the national reporting system
listed in Appendix V. By reporting side effects you can help provide more information on the safety of
this medicine.</p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store sivextro"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store sivextro"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton or blister label after
 EXP . The expiry date refers to the last day of that month.
This medicinal product does not require any special storage conditions.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to
throw away medicines you no longer use. These measures will help protect the environment.</p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Sivextro contains
* The active substance is tedizolid phosphate. Each film-coated tablet contains 200 mg of
tedizolid phosphate.
* The other ingredients are microcrystalline cellulose, mannitol, povidone, crospovidone and
magnesium stearate within the tablet core. The film coat of the tablet contains polyvinyl
alcohol, titanium dioxide (E171), macrogol, talc and yellow iron oxide (E172).
What Sivextro looks like and contents of the pack
Sivextro is an oval, yellow film-coated tablet imprinted with  TZD  on one side and  200  on the other
side.
It is available in 6   1 tablets in perforated unit-dose blisters.
Marketing Authorisation Holder and Manufacturer
Merck Sharp &amp; Dohme B.V.
Waarderweg 2031 BN Haarlem
The Netherlands
For any information about this medicine, please contact the local representative of the Marketing
Authorisation Holder:
Belgi /Belgique/Belgien
MSD Belgium
T l/Tel: +32(0)27766dpoc_belux@merck.com
Lietuva
UAB Merck Sharp &amp; Dohme
Tel.: +370 5 278 02 msd_lietuva@merck.com</p>
<p>.: +359 2 819 3info-msdbg@merck.com
Luxembourg/Luxemburg
MSD Belgium
T l/Tel: +32(0)27766dpoc_belux@merck.com
 esk  republika
Merck Sharp &amp; Dohme s.r.o.
Tel.: +420 233 010 dpoc_czechslovak@merck.com
Magyarorsz g
MSD Pharma Hungary Kft.
Tel.: +36 1 888 5hungary_msd@merck.com
Danmark
MSD Danmark ApS
Tlf: +45 4482 4dkmail@merck.com
Malta
Merck Sharp &amp; Dohme Cyprus Limited
Tel: 8007 4433 (+356 99917558)
malta_info@merck.com
Deutschland
MSD Sharp &amp; Dohme GmbH
Tel: 0800 673 673 673 (+49 (0) 89 4561 0)
e-mail@msd.de
Nederland
Merck Sharp &amp; Dohme B.V.
Tel: 0800 9999000 (+31 23 5153153)
medicalinfo.nl@merck.com
Eesti
Merck Sharp &amp; Dohme O 
Tel.: +372 6144 msdeesti@merck.com
Norge
MSD (Norge) AS
Tlf: +47 32 20 73 msdnorge@msd.no</p>
<p>MSD  . . . . .
 : +30 210 98 97 dpoc_greece@merck.com
 sterreich
Merck Sharp &amp; Dohme Ges.m.b.H.
Tel: +43 (0) 1 26 dpoc_austria@merck.com
Espa a
Merck Sharp &amp; Dohme de Espa a, S.A.
Tel: +34 91 321 06 msd_info@merck.com
Polska
MSD Polska Sp. z o.o.
Tel.: +48 22 549 51 msdpolska@merck.com
France
MSD France
T l: + 33 (0) 1 80 46 40 Portugal
Merck Sharp &amp; Dohme, Lda
Tel: +351 21 4465inform_pt@merck.com
Hrvatska
Merck Sharp &amp; Dohme d.o.o.
Tel: + 385 1 6611 croatia_info@merck.com
Rom nia
Merck Sharp &amp; Dohme Romania S.R.L.
Tel: +40 21 529 29 msdromania@merck.com
Ireland
Merck Sharp &amp; Dohme Ireland (Human Health)
Limited
Tel: +353 (0)1 2998medinfo_ireland@merck.com
Slovenija
Merck Sharp &amp; Dohme, inovativna zdravila d.o.o.
Tel: +386 1 5204 msd.slovenia@merck.com
 sland
Vistor hf.
S mi: + 354 535 7Slovensk  republika
Merck Sharp &amp; Dohme, s. r. o.
Tel.: +421 2 58282dpoc_czechslovak@merck.com
 talia
MSD Italia S.r.l.
Tel: 800 23 99 89 (+39 06 361911)
medicalinformation.it@msd.com
Suomi/Finland
MSD Finland Oy
Puh/Tel: +358 (0)9 804 info@msd.fi</p>
<p>Merck Sharp &amp; Dohme Cyprus Limited
 .: 800 00 673 (+357 22866700)
cyprus_info@merck.com
Sverige
Merck Sharp &amp; Dohme (Sweden) AB
Tel: +46 77 5700medicinskinfo@merck.com
Latvija
SIA Merck Sharp &amp; Dohme Latvija
Tel: +371 67364msd_lv@merck.com
United Kingdom (Northern Ireland)
Merck Sharp &amp; Dohme Ireland (Human Health)
Limited
Tel: +353 (0)1 2998medinfoNI@msd.com
This leaflet was last revised in {MM/YYYY}.
Detailed information on this medicine is available on the European Medicines Agency web site:
http://www.ema.europa.eu.
Package leaflet: Information for the patient
Sivextro 200 mg powder for concentrate for solution for infusion
tedizolid phosphate
Read all of this leaflet carefully before you start receiving this medicine because it contains
important information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or nurse.
- If you get any side effects, talk to your doctor or nurse. This includes any possible side effects
not listed in this leaflet. See section 4.</p>         </div>"""      





Instance: mp46f820f4ed55a5408360fa9c2e65bd6e
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Sivextro 200 mg film-coated tablets"
Description: "Sivextro 200 mg film-coated tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/15/991/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"


* indication = "Sivextro is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in"


* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"


* name
  * productName = "Sivextro 200 mg film-coated tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#DK "DK"
    * jurisdiction = urn:iso:std:iso:3166#DK "DK"
    * language = urn:ietf:bcp:47#en  "en"





                      
Instance: bundlepackageleaflet-en-4c889264e6df1e0383b0ef68358c4009
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for sivextro Package Leaflet for language en"
Description: "ePI document Bundle for sivextro Package Leaflet for language en"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "EU/1/15/991/001"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-4c889264e6df1e0383b0ef68358c4009"
* entry[0].resource = composition-en-4c889264e6df1e0383b0ef68358c4009

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp46f820f4ed55a5408360fa9c2e65bd6e"
* entry[=].resource = mp46f820f4ed55a5408360fa9c2e65bd6e
                            
                      